Alzamend Neuro, Inc. Common Stock
Symbol: ALZN (NASDAQ)
2.36
▼ (-0.63%) -0.015
Company Description:
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Key Stats
- Today's Open: $2.32
- Today's High: $2.45
- Today's Low: $2.33
- Today's Volume: 56.37K
- Yesterday Close: $2.37
- Yesterday High: $2.43
- Yesterday Low: $2.27
- Yesterday Volume: 135.88K
- Last Min Volume: 2
- Last Min High: $2.355
- Last Min Low: $2.355
- Last Min VWAP: $2.355
Company Profile
- Name: Alzamend Neuro, Inc. Common Stock
- Website: https://www.alzamend.com
- Listed Date: 2021-06-15
- Location: ATLANTA, GA
- Market Status: Active
- CIK Number: 0001677077
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $7.41M
- Round Lot: 100
- Outstanding Shares: 3.14M
- Asset Type: CS
RECENT FILINGS FOR ALZN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 10-Q | View |
| 2025-08-01 | SCHEDULE 13D/A | View |
| 2025-08-01 | 8-K | View |
| 2025-08-01 | 4 | View |
| 2025-07-29 | 4 | View |
| 2025-07-25 | 4 | View |
| 2025-07-23 | 8-K | View |
| 2025-07-22 | 10-K | View |
| 2025-07-11 | 144/A | View |
| 2025-07-09 | 8-K | View |
| 2025-05-14 | 4 | View |
| 2025-05-09 | 144 | View |
| 2025-05-08 | 8-K | View |
| 2025-04-25 | 8-K | View |
| 2025-04-09 | 424B3 | View |
| 2025-04-08 | EFFECT | View |
| 2025-04-04 | CORRESP | View |
| 2025-03-27 | S-1/A | View |
| 2025-03-27 | 4 | View |
| 2025-03-25 | 4 | View |
Latest News on ALZN